Multiple Myeloma: Molecular Pathogenesis and Disease Evolution
Oncology Research and Treatment · 2021 · 44 (12) · 672-681
DOI: 10.1159/000520312 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Oncology Research and Treatment, online erschienen am 08.11.2021. Verfasst von Michael Heider und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background: Multiple myeloma is the second most common hematologic malignancy, which to date remains incurable despite advances in treatment strategies including the use of novel substances such as proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. Summary: The bone marrow-based disease is preceded by the 2 sequential premalignant conditions: monoclonal gammopathy of undetermined significance and smoldering myeloma. Plasma cell leukemia and extramedullary disease occur, when malignant clones lose their dependency on the bone marrow. Key genetic features of these plasma cell dyscrasias include chromosomal aberrations such as translocations and hyperdiploidy, which occur during error-prone physiologic processes in B-cell development. Next-generation sequencing studies have identified mutations in major oncogenic pathways and tumor suppressors, which contribute to the pathogenesis of multiple myeloma and have revealed insights into the clonal evolution of the disease, particularly along different lines of therapy. More recently, the importance of epigenetic alterations and the role of the bone marrow microenvironment, including immune and osteogenic cells, have become evident. Key Messages: We herein review the current knowledge of the pathogenesis of multiple myeloma, which is crucial for the development of novel targeted therapeutic strategies. These can contribute to the endeavor to make multiple myeloma a curable disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
- TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.
Zitieren
APA
Heider, M., Nickel, K., Högner, M., & Bassermann, F. (2021). Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncology Research and Treatment, 44(12), 672-681. https://doi.org/10.1159/000520312
Vancouver
Heider M, Nickel K, Högner M, Bassermann F. Multiple Myeloma: Molecular Pathogenesis and Disease Evolution. Oncology Research and Treatment. 2021;44(12):672-681. doi:10.1159/000520312
BibTeX
@article{Heider2021,
author = {Heider, Michael and Nickel, Katharina and Högner, Marion and Bassermann, Florian},
title = {Multiple Myeloma: Molecular Pathogenesis and Disease Evolution},
journal = {Oncology Research and Treatment},
year = {2021},
volume = {44},
number = {12},
pages = {672--681},
doi = {10.1159/000520312}
}
EUVIMED